Clareo Health | Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
The study will consist of 2 escalating dose cohorts (groups). The study will enroll at least 6 and as many as 30 patients. All patients will receive active drug (TN-201 Gene Therapy). The study will follow patients for 5 years following a single dose of TN-201.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
MYBPC3 mutation
Hypertrophic Cardiomyopathy (obstructive and nonobstructive)
